A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 50, Issue 6, 2009, Pages 892-899

  Kaufman, Matthew ^a   Limaye, Sewanti A ^a   Driscoll, Nancy ^a   Johnson, Christina ^a   Caramanica, Angelica ^a   Lebowicz, Yehuda ^a   Patel, Dilip ^a   Kohn, Nina ^b   Rai, Kanti ^a  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b Department of Biostatistics   (United States)

Author keywords

Antibody based immunotherapy; Autoimmunity: responses to self antigen; Erythrocytes; Immunotherapeutic approaches; Lymphoid leukemia

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; RITUXIMAB;

ADULT; AGED; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CYTOPENIA; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 68449102378     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902887563     Document Type: Article

References (36)

1. Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 2006;33:230-239.
2. Hamblin TJ, Oscier DG, Young BJ. Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol 1986;39:713-716.
3. D Catovski, Goldman JM, Priesler HD. Chronic lymphocytic, prolymphocytic and hairy cell leukemia. In: Goldman JM, Priesler HD, editors, Leukaemias. London: Butterworth; 1984. pp 266-298.
4. Dearden C. Disease-specific complications of chronic lymphocytic leukemia. ASH Education Program Book 2008. p 452.
5. Hall AM, Vickers MA, McLeod E, Barker RN. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood 2005;105:2007-2015.
6. Dameshek W, Rosenthal MC. The treatment of acquired hemolytic anemia. With a note on the relationship of periarteritis nodosa to hemolytic anemia. Med Clin North Am 1951;35:1423-1440.
7. Rosenthal MC, Spaet TH, Goldenberg H, Dameshek W. Treatment of acquired haemolytic anaemia with compound F acetate. Lancet 1952;1:1135-1140.
8. Neal TF, Jr., Tefferi A, Witzig TE, Su J, Phyliky RL, Nagorney DM, Splenectomy in advanced chronic lymphocytic leukemia: A single institution experience with 50 patients. Am J Med 1992;93:435-440.
9. Akpek G, McAneny D, Weintraub L. Comparative response to splenectomy in Coombs-positive autoimmune hemolytic anemia with or without associated disease. Am J Hematol 1999;61:98-102.
10. Besa EC. Use of intravenous immunoglobulin in chronic lymphocytic leukemia. Am J Med 1984;76:209-218.
11. Besa EC. Rapid transient reversal of anemia and long-term effects of maintenance intravenous immunoglobulin for autoimmune hemolytic anemia in patients with lymphoproliferative disorders. Am J Med 1988;84:691-698.
12. Hershko C, Sonnenblick M, Ashkenazi J. Control of steroidresistant autoimmune haemolytic anaemia by cyclosporine. Br J Haematol 1990;76:436-437.
13. Ruess-Borst MA, Waller HD, Muller CA. Successful treatment of steroid-resistant hemolysis in chronic lymphocytic leukemia with cyclosporine A. Am J Hematol 1994;46: 375-376.
14. Emilia G, Messora C, Bensi L. The use of cyclosporin-A in the treatment of B-chronic lymphocytic leukemia. Leukemia 1995;9:357-359.
15. Sigler E, Shtalrid M, Goland S, Sthoeger ZM, Berrebi A. Intractable acute autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia successfully treated with vincristine-loaded platelet infusion. Am J Hematol 1995;50: 313-315.
16. Lundin J, Osterborg A. Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemia. Semin Hematol 2004;41:234-245.
17. Robak T. Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol 2004;72:79-88.
18. Reiff A. A review of Campath in autoimmune disease: Biologic therapy in the gray zone between immunosuppression and immunoablation. Hematology 2005;10:79-93.
19. Gupta N, Kavura S, Patel D, Janson D, Driscoll N, Ahmed S, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 2002;16:2092-2095.
20. Mauro FR, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Mandelli F, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000;95:2786-2792.
21. Zent CS, Schwager SM, Reinalda MS, Hoyer JD, Jelinek DF, Tschumper RC, Bowen DA, Call TG, Shanafelt TD, Kay NE, Slager SL. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol 2008;141:615-621.
22. Myint H, Copplestone JA, Orchard J, Craig V, Curtis D, Prentice AG, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995;91:341-344.
23. Dearden C, Wade R, Else M, Richards S, Milligan D, Hamblin T, et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: A beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 2008;111:1820-1826.
24. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Helsel M, Steinbrecher C, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107:885-891.
25. Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US intergroup trial E2997. J Clin Oncol 2007;25:793-798.
26. Kyasa MJ, Parrish RS, Schichman SA, Zent CS. Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol 2003;74:1-8.
27. Diehl LF, Ketchum LH. Autoimmune disease and chronic lymphocytic leukemia: Autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998;25:80-97.
28. Stahl D, Lacroix-Desmazes S, Sibrowski W, Kazatchkine MD, Kaveri SV, Broad alterations of self-reactive antibodyrepertoires of plasma IgM and IgG in B-cell chronic lymphocytic leukemia (B-CLL) and B-CLL related target-restricted autoimmunity. Leuk Lymphoma 2001;42: 163-176.
29. Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol 2000;27(6 Suppl. 12):79-85.
30. Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol 2001;114: 891-898.
31. Karlsson C, Hansson L, Celsing F, Lundin J. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia 2007;21:511-514.
32. Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786-1801.
33. Giagounidis AA, Anhuf J, Schneider P, Germing U, Sohngen D, Quabeck K, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: A pilot study. Eur J Haematol 2002;69: 95-100.
34. Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: Idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc 2003;78:1340-1346.
35. D'Arena G, Laurenti L, Capalbo S, D'Arco AM, De Fillippi R, Marcacci G, et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol 2006;81:598-602.
36. Zaja F, Vianelli N, Sperotto A, Patriarca F, Tani M, Marin L, et al. Anti-CD20 therapy for chronic lymphocytic leukemiaassociated autoimmune diseases. Leuk Lymphoma 2003;44: 1951-1955.